Biosimilars | Current Treatment | Nephrology | US/EU | 2016
The uptake of biosimilar erythropoiesis-stimulating agents (ESAs) varies from country to country, as well as by drug and manufacturer. European nephrologists have been able to prescribe ESAs to their chronic kidney disease (CKD) patients for a number of years, but no biosimilar ESAs are yet available to U.S. nephrologists. As new biosimilars near the market, including epoetin alpha biosimilars in the United States, it is important to understand how and why ESA biosimilar uptake is so varied. We surveyed French, German, and U.S. nephrologists about their familiarity with, use of, and attitude toward current biosimilars; the drivers and barriers to biosimilars’ uptake; and these physicians’ expectations for novel biosimilars.
Related Market Assessment Reports
Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete because of opioid medications. The treatment of OIC relies on various prescription medications…
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a common neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
